BioPharmSignal logoBioPharmSignal

Biotech News

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

SELLAS Life Sciences Group, Inc. (SLS)SELLAS Life Sciences Group, Inc.Company update

SLS (SLS) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is sls.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences is a biopharmaceutical company focused on oncology, especially immunotherapies for cancer. Its story is built around a small set of development assets aimed at difficult tumors.

Recent company news

SLSSELLAS Life Sciences Group, Inc.2026-05-14 12:00 EST

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

SLSSELLAS Life Sciences Group, Inc.2026-05-12 20:05 EST

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

SLSSELLAS Life Sciences Group, Inc.2026-03-19 20:05 EST

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

SLSSELLAS Life Sciences Group, Inc.2026-03-17 20:30 EST

SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference

SLSSELLAS Life Sciences Group, Inc.2026-03-12 12:35 EST

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

Stock data

Close
11.70 USD
Market cap
1.55B USD
Exchange
NASDAQ
Sector
Life Science Tools
Location
United States